Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial involved 561 people in total — 278 in one group and 283 in the other. Both groups used eye drops that combined two medicines (bimatoprost and timolol) to manage fluid pressure inside the eye, which is relevant to conditions like glaucoma. The two groups received slightly different versions of the same combination drop. The trial mainly measured the fluid pressure (called intraocular pressure, or IOP) inside the eye at several points in the day — at the start of the study and again at 2, 6, and 12 weeks. Most participants completed the trial: 269 in the first group and 271 in the second. The reported data shows that, at the start of the study, the average pressure in the more affected eye was around 25 mm Hg (millimetres of mercury, the unit used to measure eye pressure) in both groups. After 12 weeks, the reported change in that eye's pressure was a reduction of approximately 9.1 mm Hg for Formulation A and 8.7 mm Hg for the existing combination drop, measured at the first time point of the day. Similar reductions were recorded at the other two time points during the day. When looking at the average pressure across both eyes over the 12-week period, both groups recorded average eye pressure readings in the range of roughly 15.8 to 16.6 mm Hg at the various check-in times across weeks 2, 6, and 12. The reported data shows that both groups had broadly similar pressure readings across all the time points measured, though the exact numbers varied slightly between the two formulations at each check. No safety or side-effect data was included in the structured results submitted to ClinicalTrials.gov, so that information is not available here to describe. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 24667994) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Glaucoma Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with high eye pressure or glaucoma in both eyes
- You need treatment to lower the pressure in both of your eyes
Who may not be able to join:
- You have an active or returning eye disease (other than glaucoma/high eye pressure) that could affect the study results in either eye
- You have had eye surgery or laser treatment on either eye within the last 6 months
- You need to regularly use other eye drops or eye medications throughout the study period
- You plan to wear contact lenses at any point during the study
- You have used steroid medications (taken by mouth, injection into a muscle, or through a drip) on and off within the last 21 days
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Medical Director, Allergan
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
1 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Change From Baseline in Worse Eye Intraocular Pressure (IOP) at Each Hour Evaluated at Week 12; Average Eye Intraocular Pressure (IOP) at Each Hour Evaluated at Week 2; Average Eye Intraocular Pressure (IOP) at Each Hour Evaluated at Week 6; Average Eye Intraocular Pressure (IOP) at Each Hour Evaluated at Week 12
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.